NTRK1 and fibrosarcoma: In our study we revealed the suppression of confluent TRAIL resistance of HT-1080 fibrosarcoma cells by means of sorafenib, an inhibitor of some tyrosine kinase receptors (PDGFR, VEGFR) and Raf kinases [14].